TAK-071

DB18954InvestigationalSmall molecule

TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).

Chemical structure of TAK-071
Mechanism
Curator reviewed
Formula / weight
C24H24FN3O3 · 421.472 g/mol (avg)
Also known as
4-fluoro-2-((3s, 4s)-4-hydroxytetrahydro-2h-pyran-3-yl)-5-methyl-6-(4(1h-pyrazol-1-yl)benzyl)-2, 3-dihydro-1h-isoindol-1-one
Code names
TAK-071

Resolves to

Compound
UNII59XC9G796YCAS1820812-16-5ChEMBLCHEMBL4594351
Structure
InChIKeyWFSARWQASFQZMG-VXKWHMMOSA-NSMILESCC1=C(CC2=CC=C(C=C2)N2C=CC=N2)C=C2C(=O)N(CC2=C1F)[C@H]1COCC[C@@H]1O
Targets
P11229CHRM1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with TAK-071, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In